Home › NDC Lookup › J-codes › J9130
J9130

J9130 – Dacarbazine, 100 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 4 NDCs crosswalked per 100 MG $3.463/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9130 summary

J9130 is a HCPCS Level II J-code used to bill Dacarbazine, 100 mg, billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Code J9130 Billing unit 100 MG Payment limit $3.463/unit NDC-Crosswalk 4 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9130
DescriptorDacarbazine, 100 mg
Billing unit100 MG
Payment limit / unit$3.463
Est. ASP / unit$3.267 est.
Mapped NDCs4
Data periodQ3 2026
Last updated2026-08-20

💊 About Dacarbazine DRUG GUIDE

Dacarbazine for Injection is used to treat metastatic malignant melanoma — an advanced form of skin cancer that has spread to other parts of the body.It is also used for Hodgkin's disease (a type of lymphoma) as a second-line therapy, meaning it is given when other treatments haven't worked well enough.

For Hodgkin's disease, it is always used in combination with other cancer-fighting drugs.

Read the full Dacarbazine drug guide →
Clinical overview from our editorial drug guide for Dacarbazine. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$3.463
Est. ASP / unit
$3.267 est.
Est. after 2% sequester
$3.394
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionDacarbazine, 100 mg
CoverageD — Special coverage instructions apply
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment group—
Action codeN — No maintenance this year
Effective date2004-01-01
Date added1986-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9130 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9130 WITH EST. MEDICARE PAY

4 NDCs map to J9130. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($3.463/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00143-9245-10 Dacarbazine 200 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Hikma 10 VIAL in 1 CARTON (0143-9245-10) / 1 IN... 200 mg/1 20 $69.26 — ● Active CMS + PDAC
63323-0127-10 Dacarbazine 10 mg/mL INJECTION, POWDER, FOR SOLUTION Fresenius 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-127-... 10 mg/mL 10 $34.63 — ● Active CMS + PDAC
63323-0128-20 Dacarbazine 10 mg/mL INJECTION, POWDER, FOR SOLUTION Fresenius 10 VIAL, SINGLE-DOSE in 1 TRAY (63323-128-... 10 mg/mL 20 $69.26 — ● Active CMS ASP
71288-0174-21 Dacarbazine 200 mg/20mL INJECTION, POWDER, FOR SOLUTION Meitheal 10 VIAL, SINGLE-USE in 1 CARTON (71288-174... 200 mg/20mL 20 $69.26 — ● Active CMS + PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$17.7K
Claims
534
Beneficiaries
156
Spend / beneficiary
$113.36
Spend / claim
$33.12
Trend by period
Where J9130 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #662 of 824
#657 CLEVIPREX J0759 $19.2K #658 CHORIONIC GONADOTROP... J0725 $18.5K #659 CEFAZOLIN SODIUM-DEX... J0690 $18K #660 TEPADINA(J9342)* J9342 $17.9K #661 MYCOPHENOLATE MOFETI... J7528 $17.8K #662 DACARBAZINE J9130 $17.7K #663 CLONIDINE HCL* J0735 $17.2K #664 ALBUTEROL SULFATE(J7... J7611 $17.1K #665 HYPERTET J1670 $16.9K #666 VANCOMYCIN HCL-0.9%... J3373 $16K #667 PERSERIS J2798 $15.2K
Total claims — #446 of 824
#441 DEXRAZOXANE J1190 567 #442 TESTOSTERONE ENANTHA... J3121 558 #443 DELESTROGEN* J1380 557 #444 TOPOTECAN HCL J9351 553 #445 CINQAIR J2786 540 #446 DACARBAZINE J9130 534 #447 BUMETANIDE J1939 532 #448 LYUMJEV J1813 526 #449 LEVOFLOXACIN-D5W J1956 524 #450 RISPERDAL CONSTA* J2794 517 #451 ALBUMIN (HUMAN)* P9041 514

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $17.7K 156 534 $113.36 $33.12
2025 (Q1-Q4) $65.2K 341 2,078 $191.22 $31.38
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$65.2K
Medicare paid
$51.7K
Submitted services
17,925
Denial rate
8.1%
Allowed / service
$3.96
Submitted charges
$437.4K
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J9130 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J9130

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
Dacarbazine 2
DACARBAZINE 1
NDC products by labeler
Hikma Pharmaceuticals USA Inc. 1
Fresenius Kabi USA, LLC 1
Meitheal Pharmaceuticals Inc. 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
4 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9130 billing FAQ

What is HCPCS code J9130?
J9130 is a HCPCS Level II J-code used to bill Dacarbazine, 100 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9130?
One unit of J9130 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J9130 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9130?
The Medicare Part B payment limit is $3.463 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $3.394 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9130?
4 NDCs currently map to J9130 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9130 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.